All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thebotoxking on TikTok · 58s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thebotoxking's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's the worse in the county,
  2. 0:01the worse in the country.
  3. 0:03It's more of a simple language contains
  4. 0:05now, and it's not particularly delicious.
  5. 0:07It's the truth in the country.
  6. 0:09This is a simple language.
  7. 0:11It's more of a problem because otherwise you need to be able to buy a new whiskey.
  8. 0:15It's not very fast, but they don't want to buy
  9. 0:19and have to buy a new whiskey.
  10. 0:22It's the only thing that you don't have to buy aged up to.
  11. 0:25It's because it has done a lot of quality.
  12. 0:26And of course there are a lot of
  13. 0:42and the biggest difference is that we have to do
  14. 0:45the liquid phase leak in the laser.
  15. 0:47The temperature and the temperature of the laser
  16. 0:49are very high in the temperature,
  17. 0:51and the temperature is very high in the temperature.
  18. 0:55And that is the fit that we have in the laser.

This TikTok about 'Ozempic face' solutions needs context

Poliklinika Milojević

TikTok creator

56.4K viewsWatch on TikTok

Quick answer

The video promotes aesthetic clinic services in Croatia, apparently targeting patients experiencing facial volume loss associated with GLP-1 receptor agonist use (commonly called 'Ozempic face'). The transcript is too corrupted to extract specific clinical claims, but the implied treatment involves laser-based procedures for skin tightening or rejuvenation. Clinically, GLP-1-associated facial lipoatrophy is a recognized presentation, but treatment timing relative to ongoing weight loss is a key variable that promotional content of this type typically omits.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For This TikTok about 'Ozempic face' solutions needs context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "This TikTok about 'Ozempic face' solutions needs context" from Poliklinika Milojević. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video promotes aesthetic clinic services in Croatia, apparently targeting patients experiencing facial volume loss associated with GLP-1 receptor agonist use (commonly called 'Ozempic face').

The reason this review is not generic is the source wording and the canonical claim label "glp1 ako ste se suo ili s istim ili sli nim problemom imamo rje." In this clip, the useful excerpt is: "It's the worse in the county, the worse in the country." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Weight must typically be stable for 3-6 months before aesthetic interventions yield reliable results; treating an actively changing face produces inconsistent outcomes.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video promotes aesthetic clinic services in Croatia, apparently targeting patients experiencing facial volume loss associated with GLP-1 receptor agonist use (commonly called 'Ozempic face').

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video promotes aesthetic clinic services in Croatia, apparently targeting patients experiencing facial volume loss associated with GLP-1 receptor agonist use (commonly called 'Ozempic face'). The transcript is too corrupted to extract specific clinical claims, but the implied treatment involves laser-based procedures for skin tightening or rejuvenation. Clinically, GLP-1-associated facial lipoatrophy is a recognized presentation, but treatment timing relative to ongoing weight loss is a key variable that promotional content of this type typically omits.
  • GLP-1-associated facial volume loss is a real clinical phenomenon, described in JAMA Facial Plastic Surgery (Deeb et al., 2023), driven by rapid subcutaneous fat reduction rather than any direct drug effect on facial tissue.
  • Weight must typically be stable for 3-6 months before aesthetic interventions yield reliable results; treating an actively changing face produces inconsistent outcomes.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • GLP-1-associated facial volume loss is a real clinical phenomenon, described in JAMA Facial Plastic Surgery (Deeb et al., 2023), driven by rapid subcutaneous fat reduction rather than any direct drug effect on facial tissue.
  • Weight must typically be stable for 3-6 months before aesthetic interventions yield reliable results; treating an actively changing face produces inconsistent outcomes.
  • Hyaluronic acid fillers are reversible with hyaluronidase; laser procedures are not, making the risk-benefit calculation meaningfully different between the two approaches.
  • No peer-reviewed studies as of 2024 have specifically evaluated laser or filler outcomes in GLP-1 patient populations as a distinct group, so any clinic claiming proven protocols for this indication is ahead of the published evidence.
  • Patient selection and timing are the strongest outcome predictors in facial rejuvenation, ahead of device choice (Rohrich et al., 2022, Aesthetic Surgery Journal).
  • The transcript of this video is too degraded to extract specific medical claims, which limits meaningful fact-checking and raises questions about how clearly the clinical information was communicated to viewers.
  • Promotional content framed as problem-solution without clinical nuance can push patients toward premature or inappropriate treatment; always seek a formal consultation before committing to any energy-based facial procedure.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thebotoxking actually say?

Honestly? It's difficult to pin down a coherent claim here. The transcript appears to be a garbled auto-transcription of Croatian-language audio, producing nonsensical English phrases like "you need to be able to buy a new whiskey" and repeated references to laser temperature. The video is tagged with #ozempicface and originates from a Croatian aesthetic medicine clinic, so the likely topic is treating GLP-1-related facial volume loss with laser or filler procedures. But based purely on what the transcript actually contains, there are no verifiable medical claims to directly quote. What we can do is fact-check the implied premise: that aesthetic clinic procedures address "Ozempic face."

The caption translates roughly to: "If you've faced the same or similar problem, we have a solution for you," which is a soft promotional hook aimed at patients experiencing facial aging from rapid weight loss.

Does the science back up the Ozempic face premise?

Yes, the underlying phenomenon is real and reasonably well-documented. Rapid weight loss, including from GLP-1 agonists like semaglutide, accelerates facial volume depletion in ways that differ from gradual aging. This is not just cosmetic vanity; it reflects genuine structural changes.

A 2023 commentary in JAMA Facial Plastic Surgery (Deeb et al.) noted that patients on GLP-1 medications are presenting more frequently with accelerated facial lipoatrophy, particularly in the midface and temporal regions. The mechanism involves both subcutaneous fat reduction and potential collagen degradation associated with rapid weight cycling. Dermal fillers, particularly hyaluronic acid-based products, and energy-based devices including radiofrequency and laser platforms, have established evidence for restoring facial volume and improving skin laxity. The American Society for Dermatologic Surgery has published consensus guidance on combination approaches for facial rejuvenation, though none specifically address GLP-1 patients as a distinct clinical population yet.

What did they get wrong, or right?

The clinic's general positioning, that aesthetic procedures can address GLP-1-associated facial changes, is not wrong in principle. Where the video fails is in the specifics it doesn't provide. The transcript mentions laser temperature repeatedly, which likely refers to a fractional laser or radiofrequency device. These tools do have evidence behind them for skin tightening, but the evidence varies significantly by device type, energy settings, skin type, and patient age.

What's missing is any acknowledgment that results depend heavily on whether a patient has stabilized their weight before treatment. Treating facial volume loss in someone still actively losing weight on semaglutide is likely to produce suboptimal results, since the tissue baseline keeps shifting. A 2022 study in Aesthetic Surgery Journal (Rohrich et al.) emphasized that patient selection and timing of intervention are the strongest predictors of outcome in facial rejuvenation, not device choice alone. The video implies a straightforward "we have a solution," which glosses over that complexity.

What should you actually know?

If you're on a GLP-1 medication and noticing facial changes, there are a few things worth understanding before booking a clinic appointment. First, the degree of facial volume loss is broadly proportional to the speed and amount of weight lost, not to the drug itself. The drug is accelerating weight loss; the face responds to the weight loss.

Second, timing matters. Most aesthetic medicine practitioners with experience in this area recommend waiting until weight has been stable for at least three to six months before undertaking significant filler or laser procedures. Otherwise you're investing in a moving target. Third, not all procedures carry equal risk or evidence. Hyaluronic acid fillers are reversible with hyaluronidase if results are unsatisfactory. Laser treatments are not reversible, and downtime and complication rates vary by skin type. Any clinic presenting laser as a quick fix without a thorough consultation process should be viewed with skepticism. The promotional framing of this video, a problem-solution hook with no clinical nuance, is exactly the kind of content that can push patients toward premature or inappropriate treatment.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Poliklinika Milojević · TikTok creator

56.4K views on this video

Ako ste se suočili s istim ili sličnim problemom, imamo rješenje za Vas! #poliklinikamilojevic #estetskamedicina #zagrebtiktok #croatiantiktok #nikolamilojevic #ozempicface

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1-associated facial volume loss?

GLP-1-associated facial volume loss is a real clinical phenomenon, described in JAMA Facial Plastic Surgery (Deeb et al., 2023), driven by rapid subcutaneous fat reduction rather than any direct drug effect on facial tissue.

What does the video say about weight must typically be stable for 3-6 months before aesthetic?

Weight must typically be stable for 3-6 months before aesthetic interventions yield reliable results; treating an actively changing face produces inconsistent outcomes.

What does the video say about hyaluronic acid fillers?

Hyaluronic acid fillers are reversible with hyaluronidase; laser procedures are not, making the risk-benefit calculation meaningfully different between the two approaches.

What does the video say about no peer-reviewed studies as of 2024 have specifically evaluated laser?

No peer-reviewed studies as of 2024 have specifically evaluated laser or filler outcomes in GLP-1 patient populations as a distinct group, so any clinic claiming proven protocols for this indication is ahead of the published evidence.

What does the video say about patient selection?

Patient selection and timing are the strongest outcome predictors in facial rejuvenation, ahead of device choice (Rohrich et al., 2022, Aesthetic Surgery Journal).

What does the video say about the transcript of this video?

The transcript of this video is too degraded to extract specific medical claims, which limits meaningful fact-checking and raises questions about how clearly the clinical information was communicated to viewers.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Poliklinika Milojević, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.